Analyst Daniel Giraldo from Bank of America Securities maintained a Buy rating on 4D Molecular Therapeutics and keeping the price target at $31.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Daniel Giraldo has given his Buy rating due to a combination of factors that highlight the promising potential of 4D Molecular Therapeutics’ 4D-150 treatment. The long-term data for 4D-150 in treating wet age-related macular degeneration (wAMD) demonstrates a consistent durability of response, which is a critical factor for physicians. The reduction in treatment burden has been sustained over time, with a significant percentage of patients remaining injection-free, particularly among newly diagnosed individuals. This suggests a strong competitive profile for 4D-150 in the retinal disease market.
Moreover, the safety profile of 4D-150 remains highly favorable, with minimal signs of inflammation and no severe adverse events reported over an extended follow-up period. This safety aspect is seen as a key differentiator by physicians, potentially leading to broader adoption within the retinal community. Additionally, the company’s recent $100 million financing deal strengthens its financial position, supporting the advancement of phase 3 trials. These factors collectively reinforce the bullish outlook on the commercial opportunity for 4D-150, justifying the Buy rating with a price objective of $31.
FDMT’s price has also changed dramatically for the past six months – from $3.080 to $10.920, which is a 254.55% increase.